PCOS is now PMOS

If you’ve spent years living with polycystic ovary syndrome, or PCOS, you may have already seen the headlines: in May 2026, a global coalition of more than 50 patient and professional organizations — including the Endocrine Society and the American Society for Reproductive Medicine — formally renamed the condition. It’s now called polyendocrine metabolic ovarian syndrome, or PMOS.

Your diagnosis hasn’t changed. Your labs, your history, your treatment plan — none of that is different today than it was last month. What has changed is the name, and honestly, it’s about time.

Why the Name Changed

“Polycystic ovary syndrome” was always a bit of a misnomer. The follicles seen on ultrasound aren’t true cysts — they’re immature eggs that never fully matured and released. And plenty of women with the condition don’t have that ultrasound finding at all. The old name pointed to the ovaries and implied a gynecologic/fertility issue, when in reality this has always been a whole-body, multi-system hormonal condition. Reproductive symptoms are often the most visible part of it, but they’re far from the only part.

The new name — Polyendocrine Metabolic Ovarian Syndrome — reflects what specialists have understood for years: this condition involves multiple interacting endocrine systems, with metabolic consequences that reach well beyond the reproductive years. That last part is exactly what I want to talk about today, because it’s the piece that so often gets lost. PMOS doesn’t retire when your periods stop.

The PMOS Story During the Reproductive Years

Before we talk about menopause, it’s worth revisiting what PMOS actually does in the body, because the mechanisms that show up in your 20s and 30s are the same ones still running the show decades later.

Metabolic. At the core of PMOS for most women is insulin resistance — the body’s cells becoming less responsive to insulin, forcing the pancreas to produce more of it. This shows up on labs even in women who aren’t overweight. Over time, unmanaged insulin resistance raises the risk of impaired glucose tolerance, gestational diabetes, abnormal cholesterol levels (particularly low HDL and elevated triglycerides), high blood pressure, and eventually type 2 diabetes.

Weight. Insulin resistance and weight gain feed each other in a frustrating loop. Elevated insulin promotes fat storage, especially around the midsection, and that visceral fat is metabolically active — it releases inflammatory signals that worsen insulin resistance further. Many of my patients with PMOS tell me they’ve done “everything right” and still struggle with weight that doesn’t respond the way it should. That’s not a failure of willpower. It’s the physiology of the condition.

Dermatologic. Elevated androgens relative to estrogen drive the skin and hair symptoms that are often one of the most distressing parts of PMOS: persistent acne along the jawline and chin, hirsutism (excess facial or body hair), and androgenic alopecia (thinning at the crown or part line). These symptoms can be present for decades before anyone connects them back to the underlying hormonal picture.

PMOS Management in the Reproductive Years. In your 20’s and 30’s, management of PMOS revolved around whether you were trying to get pregnant or not. Fertility medications (Clomid, Femara) may have been used to increase the likelihood of ovulation and conception, and oral contraceptive pills were used to regulate bleeding and provide contraception. None of these medications “fixes” the problem, because the problem is not just in the ovaries. But where does it begin? This chicken-and-egg question deserves further investigation.

What Happens as You Move Through Menopause

Here’s the part that surprises many of my patients: menopause doesn’t resolve PMOS. It changes the picture, and in some ways, it turns the volume up.

Metabolic risk intensifies. Estrogen has a protective effect on insulin sensitivity and cardiovascular health. As estrogen declines during the menopause transition, every woman experiences some degree of increasing insulin resistance — but women with a history of PMOS are starting from an already-compromised baseline. Fasting glucose, hemoglobin A1c, and insulin levels that were borderline in your 30s and 40s can cross into frank type 2 diabetes territory in your 50s and 60s. Cardiovascular risk follows the same pattern; women with PMOS carry an estimated 1.5- to 2-fold increased risk of cardiovascular disease that persists after menopause, often compounded by higher blood pressure and unfavorable cholesterol patterns that were already present. These things together result in “Metabolic Syndrome”, the combination that worsens your risk for cardiac problems later in life.

Weight redistribution gets harder to manage. Menopause itself shifts fat storage toward the abdomen in all women, due to the loss of estrogen’s influence on fat distribution. In women with PMOS, who already have a predisposition toward central adiposity from years of insulin resistance and androgen excess, this shift is amplified. The visceral fat that accumulates is not a cosmetic issue — it’s an active driver of inflammation and further metabolic dysfunction, which is why weight management in this population deserves a more targeted approach than generic “eat less, move more” advice.

Dermatologic symptoms can persist or worsen. This is the piece I find patients are least prepared for. Androgen levels do decline with age in every woman, but in women with PMOS, androgens often remain disproportionately elevated relative to estrogen even after menopause — because the ratio between the two hormones, not just the absolute androgen level, is what drives symptoms. That means hirsutism, jawline acne, and androgenic hair thinning can continue, or worsen, well into the postmenopausal years, sometimes appearing for the first time in women whose symptoms were previously mild.

One more thing worth knowing: because years of irregular cycles mean more cumulative estrogen exposure without the protective effect of regular ovulation, women with PMOS also carry an increased lifetime risk of endometrial cancer — a reminder that gynecologic surveillance remains just as relevant after your periods have stopped. Irregular periods in perimenopause are associated with anovulation (lack of ovulation) and can lead to thickening of the endometrial lining, excessive shedding (flood gates opening kind of bleeding), and increased risk for endometrial cancer. So don’t assume this is “normal.”

The Common Thread

None of this is meant to alarm you — it’s meant to reframe the conversation. PMOS was never just a reproductive condition, and menopause doesn’t erase it; it simply shifts which symptoms are loudest. The underlying drivers — insulin resistance, androgen excess, chronic low-grade inflammation — are present at 30 and still present at 60. What changes is the environment they’re operating in, and that means your management plan should evolve too: less focus on ovulation and cycle regulation, more focus on metabolic surveillance, cardiovascular risk reduction, bone health, and targeted management of persistent androgen-driven skin and hair symptoms.

This is exactly the kind of layered, whole-person picture that gets missed when menopause care and PMOS care are treated as two separate conversations happening with two (or more) different specialists who never talk to each other.

Let’s Talk About Your Picture Specifically

If you’ve lived with PCOS — now PMOS — and you’re entering perimenopause or menopause, your history matters enormously as to how we approach this next chapter. It affects which labs are worth tracking, how we think about your cardiovascular and metabolic risk, and how we approach any symptoms you’re noticing in your skin, hair, or weight.

I’d love to talk through your specific history and what a thoughtful, individualized plan could look like for you. Schedule a Discovery Call with me to start that conversation — no pressure, just a chance to see whether working together feels like the right fit.

References

1. Teede HJ, Bahri Khomami M, Moran L, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published online May 12, 2026.
2. Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. Press release, May 12, 2026.
3. American Society for Reproductive Medicine (ASRM). PCOS is Now PMOS: Understanding the Name Change. May 2026.
4. Yale Medicine. PCOS Is Renamed PMOS: What You Need to Know. June 2026.
5. Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. Journal of Clinical Endocrinology & Metabolism. 2011;96(3):623-631.
6. PCOS Nutrition Center. PCOS, Perimenopause, and Menopause: What to Expect and How to Cope.
7. Cardiometabolic and dermatologic outcomes in postmenopausal women with a history of PCOS — clinical review summaries, Superpower Health, 2026.